Docetaxel-Induced Myositis

Thomas, Joe; Warrier, Arun; Kachare, Nanda

doi:10.1097/rhu.0000000000000888

Cited by 4 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy-induced myositis is a severe adverse event caused by chemotherapeutic agents such as immune checkpoint inhibitors (ICIs), cytotoxic agents, molecular target agents; gemcitabine, docetaxel, sunitinib, and osimertinib. [1][2][3][4][5][6][7] Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has been shown to significantly prolong progression-free survival (PFS) in advanced non-small cell lung cancer with EGFR mutation. 8) Although it is no longer the first-choice drug, it is sometimes used as monotherapy or in combination with cytotoxic agents when osimertinib is not available.…”

Section: Introductionmentioning

confidence: 99%

Gefitinib-induced Myositis: A Novel Case Report

et al. 2023

View full text Add to dashboard Cite

Chemotherapy-induced myositis is a severe adverse event caused by chemotherapeutic agents such as immune checkpoint inhibitors (ICIs) or cytotoxic agents. We experienced a patient with gefitinib-induced myositis with symptoms of muscle cramps and stiffness in the limbs, and reported the treatment process. A 70-year-old woman received four courses of carboplatin (CBDCA)+pemetrexed (PEM)+gefitinib (intravenous CBDCA area under the curve (AUC) 5 and PEM 500 mg/m 2 , every 3 weeks, and oral gefitinib 250 mg daily), for epidermal growth factor receptor (EGFR) mutation-positive stage IV lung cancer treatment; followed by seven courses of PEM+gefitinib, and continued gefitinib monotherapy thereafter. Myositis occurred 5 months after the initiation of gefitinib monotherapy. She developed strong limb cramps despite regular oral administration of 400 mg acetaminophen three times a day and complained of pain on a numeric rating scale of 10/10. Her creatine kinase (CK) was elevated from the second course of CBDCA+PEM+gefitinib but was stable at grade 1-2 thereafter. However, the muscle symptoms disappeared with CK normalization within a few days of gefitinib discontinuation due to disease progression. The Naranjo Adverse Drug Reaction Scale score was 6, suggesting a probable association. Osimertinib (an EGFR tyrosine kinase inhibitor)-induced myositis has been reported, but similar events were first observed with gefitinib in this case. Consequently, when treating with gefitinib, myositis, including the CK variation, should be monitored and appropriately managed with multidirectional treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Gefitinib-induced Myositis: A Novel Case Report

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It was observed that there were many undesirable side effects caused by weekly docetaxel treatment on epithelial ovarian cancer, such as fatigue, epiphora, nail changes and taste disturbances [ 7 ]. Recently, a case report found that docetaxel treatment may lead to myositis [ 8 , 9 ]. The side effects of docetaxel could not be ignored.…”

Section: Introductionmentioning

confidence: 99%

Combinative treatment of Curdione and docetaxel triggers reactive oxygen species (ROS)-mediated intrinsic apoptosis of triple-negative breast cancer cells

Wang

Guo

2021

Bioengineered

View full text Add to dashboard Cite

Traditional Chinese medicine Curcuma zedoary has been used for treating various diseases and cancers. However, the therapeutic effect of Curdione, one of its major components in triple negative breast cancer (TNBC) is still obscure. This study is aimed to explore whether combination of Curdione and docetaxel (DTX) could strengthen the DTX-induced pro-apoptotic effects in TNBC cells and identify its involved signaling pathways. In this study, combination of Curdione and DTX intensified the inhibited MDA-MB-468 cell proliferation and increased cell apoptosis caused by DTX treatment alone. Moreover, the combinative treatment of Curdione and DTX synergistically potentiated DTX-induced cell apoptosis by triggering reactive oxygen species (ROS) generation. Co-treatment with NAC (ROS inhibitor) could mostly block the effects induced by combination of Curdione and DTX. SB203580 (p38 inhibitor) or SC-79 (Akt activator) could partly reverse the effects induced by co-treatment, indicating that mitogen-actived protein kinases (MAPKs) and the phosphatidylinositol 3-kinases (PI3K) /Akt signaling pathway were involved in the co-treatment induced ROS-mediated cell apoptosis. To sum up, combination of Curdione and DTX enhanced the chemotherapeutic efficacy on MDA-MB-468 cells by triggering ROS-mediated cell apoptosis via MAPKs and PI3K/Akt signaling pathways. Curdione combined with DTX might have potentials application as the therapeutic strategy for TNBC. Abbreviations TNBC: triple negative breast cancer; ROS: reactive oxygen species; NAC: N-acetyl-L-cysteine; DTX: docetaxel; MAPKs: mitogen-actived protein kinases; PI3K/Akt: phosphatidylinositol 3-kinases (PI3K) /Akt; NF-Κb: the nuclear factor κB (NF-κB)

show abstract

Docetaxel

2020

Reactions Weekly

View full text Add to dashboard Cite

Docetaxel-Induced Myositis

Cited by 4 publications

References 1 publication

Gefitinib-induced Myositis: A Novel Case Report

Gefitinib-induced Myositis: A Novel Case Report

Combinative treatment of Curdione and docetaxel triggers reactive oxygen species (ROS)-mediated intrinsic apoptosis of triple-negative breast cancer cells

Docetaxel

Contact Info

Product

Resources

About